Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Optimization of Medical Time in the Emergency Department: Impact of an AI-Based System on Prescription Entry

NCT07312019 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-01
Last updated
2026-01-08

Condition(s) studied

Drug-related IatrogenesisEmergency DepartmentArtificial IntelligenceClinical Decision SupportPrescriptionTranscriptionMedicationReconciliation

Investigational drug(s) / intervention(s)

current hospital-standard databasesPosos

current hospital-standard databases: Prescription management using current hospital-standard databases and tools

Posos: Prescription management supported by POSOS device (OCR+AI) for structured data entry and clinical decision support

Study summary

Drug-related iatrogenesis is a major public health issue, accounting for a significant proportion of adverse events and hospitalizations in emergency departments. Optimizing prescription management in this context is critical to improve both patient safety and physician efficiency This study aims to evaluate the impact of the POSOS AI-driven device on the medical time required for prescription management in polymedicated patients admitted to emergency departments. The main objective is to establish whether the use of POSOS can reduce transcription time compared to standard electronic management.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years * Admission to emergency department at a participating center * Polymedicated patients with prescriptions including ≥8 medication lines (including those for long-term illnesses) * Signed informed consent Exclusion Criteria: * Patient under legal protection/judicial measures (guardianship/custody) * Lack of signed informed consent

Primary outcome measure(s)

  • Medical time required for the transcription of prescriptions — Day 1
    Medical time required for the transcription of prescriptions for at-risk polymedicated patients at emergency admission. This is measured by the duration needed to transcribe prescriptions into the structured electronic health record by physicians, assessed by direct observation with a stopwatch

Trial sites (1)

FacilityCityRegionStatus
CHU Amiens Amiens France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07312019 on ClinicalTrials.gov ↗ ← All trials in France